ADCs dynamically interact with the TME: (1) ADC-induced immunomodulation enhances sensitivity to subsequent therapies (17, 44); (2) Baseline TME features (e.g., tumour-infiltrating lymphocytes [TILs] density, IFN-γ signalling) predict ADC efficacy (12). This evidence concerns the gene IFNG and neoplasm.